CD86 and cancer: Although the lower expression of the CD80 and CD86 adhesion molecules are linked to an ineffective immune response, and consequently, to a compromised inflammatory response, studies have shown that chronic exposure to toxic agents, such as BTX compounds, could contribute to the development of an inflammatory process, which is involved in the development of different types of cancer and tumor progress [28, 29].